Tafamidis
Vyndaqel (tafamidis) is a prescription medication used to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), either hereditary or wild-type. It works by stabilizing the transthyretin protein to prevent it from misfolding into amyloid deposits that can damage the heart. This medication is specifically indicated for reducing cardiovascular mortality and hospitalization in patients with this rare but serious condition.
Vyndaqel is a transthyretin stabilizer used to treat transthyretin amyloid cardiomyopathy by preventing protein misfolding and heart damage.
Key facts at a glance
- RxNorm
- 2168543
- Generic
- Vyndaqel
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Vyndaqel is indicated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, including both hereditary forms caused by TTR gene mutations and wild-type ATTR-CM which occurs with aging without a known genetic cause. It helps reduce the risk of cardiovascular-related hospitalization and death.
Vyndaqel contains tafamidis, which binds to the transthyretin (TTR) protein and stabilizes its normal tetrameric structure. By preventing TTR from dissociating into monomers that misfold and aggregate, it reduces the formation of amyloid fibrils that deposit in the heart muscle and cause cardiomyopathy.
Vyndaqel is available in capsule form for oral administration. Common side effects may include fatigue, dizziness, or gastrointestinal symptoms. Patients should inform their doctor about all medications they are taking, as drug interactions may occur. Treatment should be initiated and monitored by physicians experienced in managing amyloidosis. The medication should not be discontinued without medical advice.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy